In:
Science Translational Medicine, American Association for the Advancement of Science (AAAS), Vol. 14, No. 650 ( 2022-06-22)
Kurzfassung:
Nonalcoholic fatty liver disease (NAFLD) raises the risk of developing hepatocellular carcinoma (HCC), but this risk can be difficult to quantify and disease onset can still be difficult to catch early. Fujiwara et al. developed hepatic transcriptome and serum secretome–derived signatures to predict NAFLD-related HCC in patients over 15 years of observation. They validated the risk signatures in independent cohorts and additionally found that one signature was altered in patients undergoing different therapeutic treatments.
Materialart:
Online-Ressource
ISSN:
1946-6234
,
1946-6242
DOI:
10.1126/scitranslmed.abo4474
Sprache:
Englisch
Verlag:
American Association for the Advancement of Science (AAAS)
Publikationsdatum:
2022
Bookmarklink